Treatment patterns, symptom reduction, quality of life, and resource use associated with lubiprostone in irritable bowel syndrome constipation subtype

Current Medical Research and Opinion

Volumn 32, Issue 5, 2016, Pages 899-905

  Solem, Caitlyn T ^a   Patel, Haridarshan ^b   Mehta, Sonam ^a   Mody, Reema ^b   Macahilig, Cynthia ^c   Gao, Xin ^a  

^a PHARMERIT INTERNATIONAL   (United States)

^b Takeda Pharmaceuticals International Inc   (United States)

^c Medical Data Analytics   (United States)

Author keywords

Chart review; Health related quality of life (HRQoL); Irritable bowel syndrome constipation (IBS C); Lubiprostone; Patient reported outcomes

Indexed keywords

LUBIPROSTONE; PROBIOTIC AGENT; SPASMOLYTIC AGENT; CHLORIDE CHANNEL STIMULATING AGENT;

ADULT; ANTISOCIAL BEHAVIOR; ARTICLE; ASSESSMENT OF HUMANS; CONSTIPATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DYSPHORIA; FEMALE; HEALTH CARE UTILIZATION; HUMAN; IRRITABLE BOWEL SYNDROME CONSTIPATION; IRRITABLE COLON; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; ONSET AGE; PATIENT ASSESSMENT; PATIENT ASSESSMENT OF CONSTIPATION SYMPTOMS; PATIENT SATISFACTION; QUALITY OF LIFE; RACE; RETROSPECTIVE STUDY; SELF REPORT; SEXUAL BEHAVIOR; TELEPHONE INTERVIEW; TIME; TREATMENT OUTCOME; COMPLICATION; HEALTH CARE PLANNING; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; QUESTIONNAIRE; YOUNG ADULT;

ADULT; CHLORIDE CHANNEL AGONISTS; CONSTIPATION; FEMALE; HEALTH RESOURCES; HUMANS; IRRITABLE BOWEL SYNDROME; LUBIPROSTONE; MIDDLE AGED; PATIENT SATISFACTION; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84964700398     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2016.1150262     Document Type: Article

References (12)

1. Bommelaer G, Poynard T, Le Pen C, et al. Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria. Gastroenterol Clin Biol 2004;28(6-7 Pt 1):554-61
2. Hillila MT, Farkkila MA. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. Aliment Pharmacol Therapeut 2004;20:339-45
3. Rey E, Talley NJ. Irritable bowel syndrome: novel views on the epidemiology and potential risk factors. Dig Liv Dis 2009;41:772-80
4. Saito YA, Schoenfeld P, Locke GR 3rd. The epidemiology of irritable bowel syndrome in North America: A systematic review. Am J Gastroenterol 2002;97:1910-15
5. Corazziari E. Definition and epidemiology of functional gastrointestinal disorders. Best Pract Res Clin Gastroenterol 2004;18:613-31
6. DiBonaventura M, Sun SX, Bolge SC, et al. Health-related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndrome. Curr Med Res Opin 2011;27:2213-22
7. Lea R, Whorwell PJ. Quality of life in irritable bowel syndrome. Pharmacoeconomics 2001;19:643-53
8. Curtis LH, Hammill BG, Eisenstein EL, et al. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care 2007;45(10 Suppl 2):S103-7
9. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: A comparative study. Stat Med 2004;23:2937-60
10. Pare P, Gray J, Lam S, et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Therapeut 2006;28:1726-35; discussion 10-11
11. Spiegel BM, Gralnek IM, Bolus R, et al. Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. Arch Intern Med 2004;164:1773-80
12. Drossman D, Morris CB, Hu Y, et al. Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. Am J Gastroenterol 2007;102:1442-53